191 related articles for article (PubMed ID: 28385551)
1. Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan.
LeVine H; Spielmann HP; Matveev S; Cauvi FM; Murphy MP; Beckett TL; McCarty K; Lott IT; Doran E; Schmitt F; Head E
Neurobiol Aging; 2017 Jun; 54():163-169. PubMed ID: 28385551
[TBL] [Abstract][Full Text] [Related]
2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
3. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
4. A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.
Matveev SV; Spielmann HP; Metts BM; Chen J; Onono F; Zhu H; Scheff SW; Walker LC; LeVine H
J Neurochem; 2014 Nov; 131(3):356-68. PubMed ID: 24995708
[TBL] [Abstract][Full Text] [Related]
5. Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology.
Hatsuta H; Takao M; Ishii K; Ishiwata K; Saito Y; Kanemaru K; Arai T; Suhara T; Shimada H; Shinotoh H; Tamaoka A; Murayama S
Curr Alzheimer Res; 2015; 12(3):278-86. PubMed ID: 25731622
[TBL] [Abstract][Full Text] [Related]
6. Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.
Hartley SL; Handen BL; Devenny D; Mihaila I; Hardison R; Lao PJ; Klunk WE; Bulova P; Johnson SC; Christian BT
Neurobiol Aging; 2017 Oct; 58():68-76. PubMed ID: 28715661
[TBL] [Abstract][Full Text] [Related]
7. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
[TBL] [Abstract][Full Text] [Related]
8. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
[TBL] [Abstract][Full Text] [Related]
9. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.
Landt J; D'Abrera JC; Holland AJ; Aigbirhio FI; Fryer TD; Canales R; Hong YT; Menon DK; Baron JC; Zaman SH
Arch Neurol; 2011 Jul; 68(7):890-6. PubMed ID: 21403005
[TBL] [Abstract][Full Text] [Related]
10. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
Chen CD; Joseph-Mathurin N; Sinha N; Zhou A; Li Y; Friedrichsen K; McCullough A; Franklin EE; Hornbeck R; Gordon B; Sharma V; Cruchaga C; Goate A; Karch C; McDade E; Xiong C; Bateman RJ; Ghetti B; Ringman JM; Chhatwal J; Masters CL; McLean C; Lashley T; Su Y; Koeppe R; Jack C; Klunk WE; Morris JC; Perrin RJ; Cairns NJ; Benzinger TLS
Acta Neuropathol; 2021 Oct; 142(4):689-706. PubMed ID: 34319442
[TBL] [Abstract][Full Text] [Related]
11. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.
Hong YT; Veenith T; Dewar D; Outtrim JG; Mani V; Williams C; Pimlott S; Hutchinson PJ; Tavares A; Canales R; Mathis CA; Klunk WE; Aigbirhio FI; Coles JP; Baron JC; Pickard JD; Fryer TD; Stewart W; Menon DK
JAMA Neurol; 2014 Jan; 71(1):23-31. PubMed ID: 24217171
[TBL] [Abstract][Full Text] [Related]
12. Postmortem Neocortical
Pivtoraiko VN; Racic T; Abrahamson EE; Villemagne VL; Handen BL; Lott IT; Head E; Ikonomovic MD
Front Aging Neurosci; 2021; 13():728739. PubMed ID: 34489686
[TBL] [Abstract][Full Text] [Related]
13. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.
Handen BL; Cohen AD; Channamalappa U; Bulova P; Cannon SA; Cohen WI; Mathis CA; Price JC; Klunk WE
Alzheimers Dement; 2012 Nov; 8(6):496-501. PubMed ID: 23102120
[TBL] [Abstract][Full Text] [Related]
14. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.
Burack MA; Hartlein J; Flores HP; Taylor-Reinwald L; Perlmutter JS; Cairns NJ
Neurology; 2010 Jan; 74(1):77-84. PubMed ID: 20038776
[TBL] [Abstract][Full Text] [Related]
15. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline.
Cole JH; Annus T; Wilson LR; Remtulla R; Hong YT; Fryer TD; Acosta-Cabronero J; Cardenas-Blanco A; Smith R; Menon DK; Zaman SH; Nestor PJ; Holland AJ
Neurobiol Aging; 2017 Aug; 56():41-49. PubMed ID: 28482213
[TBL] [Abstract][Full Text] [Related]
16. Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.
Schultz AP; Kloet RW; Sohrabi HR; van der Weerd L; van Rooden S; Wermer MJH; Moursel LG; Yaqub M; van Berckel BNM; Chatterjee P; Gardener SL; Taddei K; Fagan AM; Benzinger TL; Morris JC; Sperling R; Johnson K; Bateman RJ; ; Gurol ME; van Buchem MA; Martins R; Chhatwal JP; Greenberg SM
Ann Neurol; 2019 Oct; 86(4):616-625. PubMed ID: 31361916
[TBL] [Abstract][Full Text] [Related]
17. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE
Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
[TBL] [Abstract][Full Text] [Related]
18. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
Johnson KA; Gregas M; Becker JA; Kinnecom C; Salat DH; Moran EK; Smith EE; Rosand J; Rentz DM; Klunk WE; Mathis CA; Price JC; Dekosky ST; Fischman AJ; Greenberg SM
Ann Neurol; 2007 Sep; 62(3):229-34. PubMed ID: 17683091
[TBL] [Abstract][Full Text] [Related]
19. The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis.
Annus T; Wilson LR; Acosta-Cabronero J; Cardenas-Blanco A; Hong YT; Fryer TD; Coles JP; Menon DK; Zaman SH; Holland AJ; Nestor PJ
Neurobiol Aging; 2017 May; 53():11-19. PubMed ID: 28192686
[TBL] [Abstract][Full Text] [Related]
20. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
